The Michigan Department of Health is offering the Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study Grant for research on systemic lupus erythematosus (SLE) to understand treatment, health care access, natural history, and related outcomes over time. This grant aims to investigate factors influencing outcomes and disparities in gender and race/ethnicity within a population-based cohort to enhance the epidemiologic understanding of SLE and its burden on the population.
Opportunity ID: 280386
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DP-16-002 |
| Funding Opportunity Title: | Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.283 — Centers for Disease Control and Prevention_Investigations and Technical Assistance |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Dec 07, 2015 |
| Last Updated Date: | Feb 08, 2016 |
| Original Closing Date for Applications: | Feb 05, 2016 Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date. |
| Current Closing Date for Applications: | Feb 10, 2016 Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date. |
| Archive Date: | Mar 06, 2016 |
| Estimated Total Program Funding: | $3,000,000 |
| Award Ceiling: | $1,000,000 |
| Award Floor: | $750,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Additional Information on Eligibility – The only organization eligible to apply for this funding opportunity annoucement is the University of Michigan. |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | Lupus is a prototypical autoimmune disease with a wide spectrum of illness that can be limited to the skin or can affect almost any tissue and organ in the body and cause severe morbidity and premature mortality. While there are several forms of lupus, systemic lupus erythematous (SLE) is the most common and serious form of lupus and has a variety of clinical manifestations. SLE affects from 320,000 to 1.5 million Americans and has strong disparities in incidence and prevalence, affecting women far more than men and minorities more than whites. The causes of SLE are unknown but are believed to be linked to genetic, environmental, and hormonal factors. Much of what is known about SLE comes from convenience samples and tertiary care centers that are not population-based and therefore biased toward the severe end of the disease spectrum. As a result there is a need for a basic epidemiologic understanding of SLE in order to understand the full clinical spectrum and population burden of the disease. The purpose of this funding announcement is to support a longitudinal study to follow an established population-based cohort with SLE to determine over time: 1) the treatment, health care access, and natural history (severity, morbidity, mortality, etc.) of lupus (systemic lupus erythematosus) and related outcomes; 2) factors (including genetic and other biological factors such as antibody levels) associated with outcomes of treatment, health care access and natural history; and 3) potential disparities and other factors associated with outcomes by categories of interest (e.g., gender and race/ethnic group). |
| Link to Additional Information: | |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Sue Shaw
ZGX7@cdc.gov Email:ZGX7@cdc.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The closing date has been update from February 05, 2016 to February 10, 2016 at 5 p.m.. | Feb 08, 2016 | |
| The closing date has been update from February 05, 2016 to February 10, 2016 at 5 p.m.. | Feb 08, 2016 | |
| Feb 08, 2016 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DP-16-002 |
| Funding Opportunity Title: | Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.283 — Centers for Disease Control and Prevention_Investigations and Technical Assistance |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Dec 07, 2015 |
| Last Updated Date: | Feb 08, 2016 |
| Original Closing Date for Applications: | Feb 05, 2016 Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date. |
| Current Closing Date for Applications: | Feb 10, 2016 Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date. |
| Archive Date: | Mar 06, 2016 |
| Estimated Total Program Funding: | $3,000,000 |
| Award Ceiling: | $1,000,000 |
| Award Floor: | $750,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Additional Information on Eligibility – The only organization eligible to apply for this funding opportunity annoucement is the University of Michigan. |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | Lupus is a prototypical autoimmune disease with a wide spectrum of illness that can be limited to the skin or can affect almost any tissue and organ in the body and cause severe morbidity and premature mortality. While there are several forms of lupus, systemic lupus erythematous (SLE) is the most common and serious form of lupus and has a variety of clinical manifestations. SLE affects from 320,000 to 1.5 million Americans and has strong disparities in incidence and prevalence, affecting women far more than men and minorities more than whites. The causes of SLE are unknown but are believed to be linked to genetic, environmental, and hormonal factors. Much of what is known about SLE comes from convenience samples and tertiary care centers that are not population-based and therefore biased toward the severe end of the disease spectrum. As a result there is a need for a basic epidemiologic understanding of SLE in order to understand the full clinical spectrum and population burden of the disease. The purpose of this funding announcement is to support a longitudinal study to follow an established population-based cohort with SLE to determine over time: 1) the treatment, health care access, and natural history (severity, morbidity, mortality, etc.) of lupus (systemic lupus erythematosus) and related outcomes; 2) factors (including genetic and other biological factors such as antibody levels) associated with outcomes of treatment, health care access and natural history; and 3) potential disparities and other factors associated with outcomes by categories of interest (e.g., gender and race/ethnic group). |
| Link to Additional Information: | |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Sue Shaw
ZGX7@cdc.gov Email:ZGX7@cdc.gov |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DP-16-002 |
| Funding Opportunity Title: | Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.283 — Centers for Disease Control and Prevention_Investigations and Technical Assistance |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Feb 08, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Feb 05, 2016 Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date. |
| Archive Date: | Mar 06, 2016 |
| Estimated Total Program Funding: | $3,000,000 |
| Award Ceiling: | $1,000,000 |
| Award Floor: | $750,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Additional Information on Eligibility – The only organization eligible to apply for this funding opportunity annoucement is the University of Michigan. |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | Lupus is a prototypical autoimmune disease with a wide spectrum of illness that can be limited to the skin or can affect almost any tissue and organ in the body and cause severe morbidity and premature mortality. While there are several forms of lupus, systemic lupus erythematous (SLE) is the most common and serious form of lupus and has a variety of clinical manifestations. SLE affects from 320,000 to 1.5 million Americans and has strong disparities in incidence and prevalence, affecting women far more than men and minorities more than whites. The causes of SLE are unknown but are believed to be linked to genetic, environmental, and hormonal factors. Much of what is known about SLE comes from convenience samples and tertiary care centers that are not population-based and therefore biased toward the severe end of the disease spectrum. As a result there is a need for a basic epidemiologic understanding of SLE in order to understand the full clinical spectrum and population burden of the disease. The purpose of this funding announcement is to support a longitudinal study to follow an established population-based cohort with SLE to determine over time: 1) the treatment, health care access, and natural history (severity, morbidity, mortality, etc.) of lupus (systemic lupus erythematosus) and related outcomes; 2) factors (including genetic and other biological factors such as antibody levels) associated with outcomes of treatment, health care access and natural history; and 3) potential disparities and other factors associated with outcomes by categories of interest (e.g., gender and race/ethnic group). |
| Link to Additional Information: | |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Sue Shaw
ZGX7@cdc.gov Email:ZGX7@cdc.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DP-16-002 |
| Funding Opportunity Title: | Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.283 — Centers for Disease Control and Prevention_Investigations and Technical Assistance |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 08, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Feb 05, 2016 Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date. |
| Archive Date: | Mar 06, 2016 |
| Estimated Total Program Funding: | $3,000,000 |
| Award Ceiling: | $1,000,000 |
| Award Floor: | $750,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Additional Information on Eligibility – The only organization eligible to apply for this funding opportunity annoucement is the University of Michigan. |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention – ERA |
| Description: | Lupus is a prototypical autoimmune disease with a wide spectrum of illness that can be limited to the skin or can affect almost any tissue and organ in the body and cause severe morbidity and premature mortality. While there are several forms of lupus, systemic lupus erythematous (SLE) is the most common and serious form of lupus and has a variety of clinical manifestations. SLE affects from 320,000 to 1.5 million Americans and has strong disparities in incidence and prevalence, affecting women far more than men and minorities more than whites. The causes of SLE are unknown but are believed to be linked to genetic, environmental, and hormonal factors. Much of what is known about SLE comes from convenience samples and tertiary care centers that are not population-based and therefore biased toward the severe end of the disease spectrum. As a result there is a need for a basic epidemiologic understanding of SLE in order to understand the full clinical spectrum and population burden of the disease. The purpose of this funding announcement is to support a longitudinal study to follow an established population-based cohort with SLE to determine over time: 1) the treatment, health care access, and natural history (severity, morbidity, mortality, etc.) of lupus (systemic lupus erythematosus) and related outcomes; 2) factors (including genetic and other biological factors such as antibody levels) associated with outcomes of treatment, health care access and natural history; and 3) potential disparities and other factors associated with outcomes by categories of interest (e.g., gender and race/ethnic group). |
| Link to Additional Information: | |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Sue Shaw
ZGX7@cdc.gov Email:ZGX7@cdc.gov |
Related Documents
Folder 280386 Full Announcement-1 -> rfa-dp16-002 final 02 08 16.pdf
Packages
| Agency Contact Information: | Sue Shaw ZGX7@cdc.gov Email: ZGX7@cdc.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.283 | RFA-DP-16-002 | Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study | PKG00219980 | Dec 07, 2015 | Feb 10, 2016 | View |
Package 1
Mandatory forms
280386 RR_SF424_2_0-2.0.pdf
280386 PHS398_CoverPageSupplement_2_0-2.0.pdf
280386 PerformanceSite_2_0-2.0.pdf
280386 RR_OtherProjectInfo_1_3-1.3.pdf
280386 RR_KeyPersonExpanded_2_0-2.0.pdf
280386 PHS398_ResearchPlan_2_0-2.0.pdf
Optional forms
280386 PHS398_CumulativeInclusionReport-1.0.pdf
280386 PlannedReport-1.0.pdf
280386 RR_SubawardBudget30_1_3-1.3.pdf
280386 PHS398_ModularBudget_1_2-1.2.pdf
280386 RR_Budget_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
